EXEL
ExelixisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The Q1 print showed continued cabozantinib franchise growth, with net product revenue up year over year on volume, while management kept 2026 guidance unchanged and reiterated a dense zanzalintinib milestone calendar. Post-earnings target increases from Morgan Stanley, Stifel, TD Cowen, and H.C.
Posture
Constructive
Lead driver
Momentum
What changed
4 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Cabozantinib still accounts for the majority of revenue, leaving the story exposed to single-franchise concentration risk [#10-Q-2026-05-05].
Momentum
77
Value
65
Sentiment
49
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $48.00 · Bull $56.00 · Bear $39.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $46.83
Why
Momentum77 · Δ7d +0.5
Value65 · Δ7d +0.1
Sentiment49 · Δ7d +2.7
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
77
34% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+17.2
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
49
33% active weight
Current posture
7d trendImproving
Δ7d
+2.7
Δ21d
+6.5
Why this grade
Composite grade A. Momentum 77.4 / Value 65.4 / Sentiment 48.9
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$12.64B
Beta
0.42
Shares Out
268.11M
P/E (TTM)
17.9
P/S (TTM)
4.97
P/FCF (TTM)
14.58
Rev YoY
+10.8%
EPS YoY
+71.7%
Gross Margin
+96.6%
Op Margin
+35.0%
Net Debt
-$1.11B
Current Ratio
3.75
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology